What's new? Log in Free sign up

Inhibrx Biosciences (INBX)

Company Profile

Company profile

Ticker

INBX

Exchange

Website

CEO

Mr. Mark Paul Lappe

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Moderna • Bio-Techne • Acorda Therapeutics • Mach Natural Resources ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

824257312

INBX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Securities registration termination

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Automatic shelf registration (post-effective amendment)

Termination of a Material Definitive Agreement

Exchange delisting

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Additional proxy soliciting materials

Latest ownership filings

View all

PERCEPTIVE ADVISORS LLC

VIKING GLOBAL INVESTORS LP

OLE ANDREAS HALVORSEN

Inhibrx Biosciences, Inc.

Kristiina MD Vuori

KIMBERLY MANHARD

Jon Faiz Kayyem

DOUGLAS FORSYTH

Brendan P. Eckelman

Financial summary

Financial statements Chart INBX financial data

Quarter (USD)	Mar 24	Dec 23	Sep 23	Jun 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	252.48 mm	252.48 mm	252.48 mm	252.48 mm	252.48 mm	252.48 mm
Cash burn (monthly)	8.48 mm	(no burn)	26.24 mm	22.15 mm	21.02 mm	18.03 mm
Cash used (since last report)	84.74 mm	n/a	262.16 mm	221.35 mm	210.00 mm	180.20 mm
Cash remaining	167.75 mm	n/a	-9.68 mm	31.13 mm	42.48 mm	72.28 mm
Runway (months of cash)	19.8	n/a	-0.4	1.4	2.0	4.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

INBX institutional ownership history Ownership history

1.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	126	-99.2%
Opened positions	0	53	EXIT
Closed positions	125	20	+525.0%
Increased positions	0	25	EXIT
Reduced positions	0	30	EXIT

13F shares	Current	Prev Q	Change
Total value	6.64 mm	1.31 tn	-100.0%
Total shares	151.99 k	38.11 mm	-99.6%
Total puts	0.00	91.30 k	EXIT
Total calls	0.00	64.82 k	EXIT
Total put/call ratio	–	1.4	–

Largest owners	Shares	Value	Change
LAV Summit	151.99 k	$6.64 mm	0.0%
Viking Global Investors	0.00	$0.00	EXIT

Largest transactions	Shares	Bought/sold	Change
Viking Global Investors	0.00	-7.15 mm	EXIT
Perceptive Advisors	0.00	-4.26 mm	EXIT
BLK BlackRock	0.00	-2.75 mm	EXIT
Ra Capital Management	0.00	-2.63 mm	EXIT
STT State Street	0.00	-2.42 mm	EXIT
Vanguard	0.00	-1.86 mm	EXIT
TCG Crossover Management	0.00	-1.75 mm	EXIT
Sofinnova Investments	0.00	-1.30 mm	EXIT
Citadel Advisors	0.00	-1.20 mm	EXIT
Alpine Associates Management	0.00	-1.05 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

INBX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 May 24	Jon Faiz Kayyem	Common Stock	Sale back to company	Dispose D	Yes	No	30	25,000	750.00 k	0
30 May 24	Jon Faiz Kayyem	Common Stock	Sale back to company	Dispose D	Yes	No	30	25,000	750.00 k	0
30 May 24	Jon Faiz Kayyem	Common Stock	Sale back to company	Dispose D	Yes	No	30	3,224,301	96.73 mm	0
30 May 24	Jon Faiz Kayyem	Stock Option Common Stock	Sale back to company	Dispose D	No	No	24.78	15,000	371.70 k	0
30 May 24	Jon Faiz Kayyem	Stock Option Common Stock	Sale back to company	Dispose D	No	No	12.57	15,000	188.55 k	0
30 May 24	Jon Faiz Kayyem	Stock Option Common Stock	Sale back to company	Dispose D	No	No	23.03	15,000	345.45 k	0
30 May 24	Jon Faiz Kayyem	Stock Option Common Stock	Sale back to company	Dispose D	No	No	10.52	17,259	181.56 k	0
30 May 24	Manhard Kimberly	Stock Option Common Stock	Sale back to company	Dispose D	No	No	20.43	17,259	352.60 k	0
30 May 24	Manhard Kimberly	Stock Option Common Stock	Sale back to company	Dispose D	No	No	24.78	15,000	371.70 k	0
30 May 24	Manhard Kimberly	Stock Option Common Stock	Sale back to company	Dispose D	No	No	12.57	15,000	188.55 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

JMP Securities analyst Reni Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.

Inhibrx Reports Preliminary Efficacy And Safety Data From Phase 1 Trial Of Ozekibart (INBRX-109) For Treatment Of Colorectal Cancer; Initiates New Expansion Cohort To Validate Findings

Efficacy was assessed in 10 of the 13 patients who received at least one dose of ozekibart, based on RECIST v1.1 criteria. Results demonstrated one complete response (CR), three partial responses (PR), and six cases of

Inhibrx Biosciences Q3 EPS $(2.84) Beats $(3.81) Estimate

Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.81) by 25.46 percent. This is a 35.31 percent increase over losses of $(4.39) per share

Inhibrx Announces The Jury Found In Favor Of Inhibrx, Rejecting All Allegations Of Misappropriation Before It, Confirming The Company's Adherence To High Ethical Standards And Innovation In Scientific Research, Reaffirming Its Commitment To Integrity And Innovation

Press releases

From Benzinga Pro

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (NASDAQ:INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.